Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells

Experimental Cell Research

Volumn 312, Issue 12, 2006, Pages 2203-2213

  Díaz, Víctor M ^a,b,c   Hurtado, Mariano ^a   Kort, Eric J ^d   Resnati, Massimo ^e   Blasi, Francesco ^e   Thomson, Timothy ^b   Paciucci, Rosanna ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Colon cancer; Phorbol esters; Plasmin; Scatter; Urokinase; Urokinase receptor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; AMILORIDE; APROTININ; ILOMASTAT; LEUPEPTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUTRALIZING ANTIBODY; PAI 1; PEPSTATIN; PERTUSSIS TOXIN; PHORBOL ESTER; PLASMIN; PLASMINOGEN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL; CELL STRAIN HT29; CLINICAL OBSERVATION; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 33745245558     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.03.017     Document Type: Article

References (45)

1. Murphy G., and Gavrilovic J. Proteolysis and cell migration: creating a path?. Curr. Opin. Cell Biol. 11 (1999) 614-621
2. Mondino A., and Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 25 (2004) 450-455
3. Sidenius N., and Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 22 (2003) 205-222
4. Blasi F., and Carmeliet P. uPAR: a versatile signaling orchestrator. Nat. Rev., Mol. Cell Biol. 3 (2003) 932-943
5. Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F., and Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15 (1996) 1572-1582
6. Fazioli F., Resnati M., Sidenius N., Higashimoto Y., Appella E., and Blasi F. A urokinase-sensitive receptor of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16 (1997) 7279-7286
7. Lesuffleur T., Barbat A., Dussaulx E., and Zweibaum A. Growth adaptation to methotrexate of HT29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells. Cancer Res. 50 (1990) 6334-6443
8. Garcia de Herreros A., Fabre M., Batlle E., Balague C., and Real F.X. The tumor promoter 12-O-tetradecanoylphorbol-13-acetate blocks differentiation of HT29 human colon cancer cells. J. Cell Sci. 105 (1993) 1165-1172
9. Fabre M., and Garcia de Herreros A. Phorbol ester-induced scattering of HT29 human intestinal cancer cells is associated with down-modulation of E-cadherin. J. Cell Sci. 106 (1993) 513-521
10. Skoudy A., and Garcia de Herreros A. The protein kinase C activator TPA modulates cellular levels and distribution of E-cadherin in HT29 human intestinal epithelial cells. FEBS Lett. 374 (1995) 415-418
11. Llosas M.D., Batlle E., Coll O., Skoudy A., Fabre M., and Garcia de Herreros A. Evidence for a role of conventional protein kinase-C alpha in the control of homotypic contacts and cell scattering of HT29 human intestinal cells. Biochem. J. 315 (1996) 1049-1054
12. Batlle E., Verdu J., Dominguez D., Del Mont Llosa M., Diaz V., Loukili N., Paciucci R., Alameda F., and De Herreros A.G. Protein kinase C-alpha activity inversely modulates invasion and growth of intestinal cells. J. Biol. Chem. 273 (1998) 15091-15098
13. O'Brian A., Ward N.E., Gravitt K.R., and Gupta K.P. The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. Prog. Clin. Biol. Res. 391 (1995) 117-120
14. Hajjar K.A. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J. Biol. Chem. 266 (1991) 21962-21970
15. Ridler T., and Calvard S. Picture thresholding using an iterative selection method. IEEE Trans. Syst. Man Cybern., SMC 8 (1978) 630-632
16. Kort E.J., Jones A., Daumbach M., Hudson E.A., Buckner B., and Resau J.H. Quantifying cell scattering: the Blob algorithm revisited. Cytometry 51A 2 (2003) 119-126 (Feb.)
17. Russ J.C. The image processing handbook. 4th ed. (2002), CRC Press, Boca Raton, FLA
18. Paciucci R., Vila M.R., Adell T., Diaz V., Torá M., Nakamura T., and Real F.X. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. Am. J. Pathol. 153 (1998) 201-212
19. Paciucci R., Tora M., Diaz V.M., and Real F.X. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene 16 (1998) 625-633
20. Herrera R. Modulation of hepatocyte growth factor-induced scattering of HT29 colon carcinoma cells. J. Cell Sci. 111 (1998) 1039-1049
21. Isseroff R.R., and Rifkin D.B. Plasminogen is present in the basal layer of epidermis. J. Invest. Dermatol. 80 (1983) 297-299
22. Vassalli J.D., and Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 214 (1987) 187-191
23. Galardy R.E., Grobelny D., Foellmer H.G., and Fernandez L.A. Inhibition of angiogenesis by the matrix metalloproteinase inhibitor N-[2R-2-(hydroxamidocarbonymethyl)-4-methylpentanoyl)]-l-tryptophan methylamide. Cancer Res. 54 (1994) 4715-4718
24. Pepper M., Matsumoto K., Nakamura T., Orci L., and Montesano R. Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J. Biol. Chem. 267 (1992) 20493-20496
25. Jeffers M., Rong S., and Vande Woude G.F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol. Cell. Biol. 16 (1996) 1115-1125
26. Ried S., Jager C., Jeffers M., Vande Woude G.F., Graeff H., Schmitt M., and Lengyel E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J. Biol. Chem. 274 (1999) 16377-16386
27. Yebra M., Goretzki L., Pfeifer M., and Mueller B.M. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp. Cell Res. 250 (1999) 231-240
28. Hoyer-Hansen G., Ploug M., Behrendt N., Ronne E., and Dano K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur. J. Biochem. 243 (1997) 21-26
29. Liu D., Aguirre Ghiso J., Estrada Y., and Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1 5 (2002) 445-457
30. Jo M., Thomas K.S., O'Donnell D.M., and Gonias S.L. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J. Biol. Chem. 278 (2003) 1642-1646
31. Jo M., Thomas K.S., Marozkina N., Amin T.J., Silva C.M., Parsons S.J., and Gonias S.L. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J. Biol. Chem. 280 17 (2005) 17449-17457
32. Skoudy A., Llosas M.D., and Garcia de Herreros A. Intestinal HT29 cells with dysfunction of E-cadherin show increased pp60Src activity and tyrosine phosphorylation of p120-catenin. Biochem. J. 317 (1996) 279-284
33. Perl A.K., Wilgenbus P., Dahl U., Semb H., and Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392 (1998) 190-193
34. Conacci-Sorrell M., Zhurinsky J., and Ben-Ze'ev. The cadherin-catenin adhesion system in signaling and cancer. J. Clin. Invest. 109 (2002) 987-991
35. Herren T., Swaisgood C., and Plow E.F. Regulation of plasminogen receptors. Front. Biosci. 8 (2003) d1-d8
36. Lund L.R., Ronne E., Roldan A.L., Behrendt N., Romer J., and Blasi F. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J. Biol. Chem. 266 (1991) 5177-5181
37. Wang H., Skibber J., Juarez J., and Boyd D. Transcription activation of the urokinase receptor gene in invasive colon cancer. Int. J. Cancer 58 (1994) 650-657
38. Wilson A.J., and Gibson P.R. Role of urokinase and its receptor in basal and stimulated colonic epithelial cell migration in vitro. Gut 47 (2000) 105-111
39. Solberg H., Romer J., Brunner N., Holm A., Sidenius N., Dano K., and Hoyer-Hansen G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int. J. Cancer 58 (1994) 877-881
40. Ragno P., Montuori N., Covelli B., Hoyer-Hansen G., and Rossi G. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells. Cancer Res. 58 (1998) 1315-1319
41. Sidenius N., Sier C.F., and Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 475 (2000) 52-56
42. Sier C.F., Stephens R., Bizik J., Mariani A., Bassan M., Pedersen N., Frigerio L., Ferrari A., Dano K., Brunner N., and Blasi F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 58 (1998) 1843-1849
43. Sier C.F., Sidenius N., Mariani A., Aletti G., Agape V., Ferrari A., Casetta G., Stephens R.W., Brunner N., and Blasi F. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab. Invest. 79 (1999) 717-722
44. Pendurthi U.R., Ngyuen M., Andrade-Gordon P., Pedersen L.C., and Rao L.V. Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway. Arterioscler., Thromb., Vasc. Biol. 22 (2002) 1421-1426
45. Majumdar M., Tarui T., Shi B., Akakura N., Ruf W., and Takada Y. Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin {alpha}9{beta}1. J. Biol. Chem. 279 (2004) 37528-37534